Lundin Law PC announces a class action lawsuit has been filed against CTI BioPharma Corp. ("CTI BioPharma" or the "Company") (Nasdaq: CTIC) concerning possible violations of federal securities laws between March 4, 2014 and February 9, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the April 11, 2016, lead plaintiff motion deadline.

For more information or to participate, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, the Company failed to disclose that: (1) CTI BioPharma's clinical trials showed that patient deaths were related to pacritinib usage; (2) CTI BioPharma's application for the approval of pacritinib would likely be withdrawn; (3) the Company's future revenues were impaired; and (4) that the company lacked adequate internal controls.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on

Copyright Business Wire 2010